Development of recombinant allergens for diagnosis and therapy

Frontiers in Bioscience - Elite

Volumn 1 E, Issue 1, 2009, Pages 77-90

  Egger, Matthias ^a   Hauser, Michael ^a   Himly, Martin ^a   Wopfner, Nicole ^a   Wallner, Michael ^a   Ferreira, Fatima ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergen extracts; Allergen specific immunotherapy; Allergy diagnosis; Hypoallergens; Recombinant allergens; Review

Indexed keywords

ALLERGEN; DIAGNOSTIC AGENT; IMMUNOGLOBULIN E; RECOMBINANT PROTEIN;

HUMAN; HYPERSENSITIVITY; METABOLISM; REVIEW;

ALLERGENS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; RECOMBINANT PROTEINS;

EID: 74349117314     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Parronchi P, Brugnolo F, Sampognaro S, Maggi E: Genetic and environmental factors contributing to the onset of allergic disorders. Int Arch Allergy Immunol 121, 2-9 (2000) (Pubitemid 30079539)
2. von Mutius E: The environmental predictors of allergic disease. J Allergy Clin Immunol 105, 9-19 (2000) (Pubitemid 30059097)
3. Blackley C: Experimental Researches on the Causes and Nature of Catarrhus aestivus. London: Balliere, Tindall, Cox (1873)
4. Freeman J: Vaccination against hay fever: report of results during the first three years.
5. Noon L: Prophylactic inoculation against hay fever. Lancet 1, 1572-1573 (1911)
6. Kim DS, Drake-Lee AB: Allergen immunotherapy in ENT: historical perspective. J Laryngol Otol 117, 940-945 (2003) (Pubitemid 38031020)
7. Frew AJ: 25. Immunotherapy of allergic disease. J Allergy Clin Immunol 111, 712-719 (2003)
8. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81, 401-405 (1998)
9. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341, 468-475 (1999) (Pubitemid 29372886)
10. Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M, Wopfner N, et al: Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5, 5-14 (2006) (Pubitemid 43796677)
11. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Bmj 302, 265-269 (1991)
12. Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6, 761-771 (2006) (Pubitemid 44453462)
13. Wallner M, Briza P, Thalhamer J, Ferreira F: Specific immunotherapy in pollen allergy. Curr Opin Mol Ther 9, 160-167 (2007) (Pubitemid 46623948)
14. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, et al: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 29, 2026-2036 (1999) (Pubitemid 29265559)
15. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57, 423-430 (2002) (Pubitemid 34442156)
16. Bohle B, Vieths S: Improving diagnostic tests for food allergy with recombinant allergens. Methods 32, 292-299 (2004) (Pubitemid 38201283)
17. van Ree R: The CREATE project: EU support for the improvement of allergen standardization in Europe. Allergy 59, 571-574 (2004) (Pubitemid 38748053)
18. Akdis CA, Blaser K: Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 121, 261-269 (2000) (Pubitemid 30229638)
19. Bhalla PL: Genetic engineering of pollen allergens for hayfever immunotherapy. Expert Rev Vaccines 2, 75-84 (2003) (Pubitemid 36559941)
20. Chapman MD, Smith AM, Vailes LD, Arruda LK, Dhanaraj V, Pomes A: Recombinant allergens for diagnosis and therapy of allergic disease. J Allergy Clin Immunol 106, 409-418 (2000) (Pubitemid 32037691)
21. Singh MB, de Weerd N, Bhalla PL: Genetically engineered plant allergens with reduced anaphylactic activity. Int Arch Allergy Immunol 119, 75-85 (1999) (Pubitemid 29304462)
22. Valenta R: The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2, 446-453 (2002) (Pubitemid 37328752)
23. Valenta R, Vrtala S, Focke-Tejkl M, Bugajska S, Ball T, Twardosz A, et al: Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol Chem 380, 815-824 (1999) (Pubitemid 29412738)
24. Egger M, Mutschlechner S, Wopfner N, Gadermaier G, Briza P, Ferreira F: Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view. Allergy 61, 461-476 (2006) (Pubitemid 43334116)
25. Johansson SG: ImmunoCAP Specific IgE test: an objective tool for research and routine allergy diagnosis. Expert Rev Mol Diagn 4, 273-279 (2004) (Pubitemid 38684704)
26. King EM, Vailes LD, Tsay A, Satinover SM, Chapman MD: Simultaneous detection of total and allergen-specific IgE by using purified allergens in a fluorescent multiplex array. J Allergy Clin Immunol 120, 1126-1131 (2007) (Pubitemid 350029889)
27. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, et al: Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. Faseb J 16, 414-416 (2002)
28. Jahn-Schmid B, Harwanegg C, Hiller R, Bohle B, Ebner C, Scheiner O, et al: Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. Clin Exp Allergy 33, 1443-1449 (2003) (Pubitemid 37289943)
29. Wohrl S, Vigl K, Zehetmayer S, Hiller R, Jarisch R, Prinz M, et al: The performance of a component-based allergen-microarray in clinical practice. Allergy 61, 633-639 (2006)
30. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K: Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 28, 914-925 (1998) (Pubitemid 28116205)
31. Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, et al: Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. Faseb J 12, 231-242 (1998) (Pubitemid 28080193)
32. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, et al: The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 154, 6285-6290 (1995)
33. van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML: Serum-IgEfacilitated allergen presentation in atopic disease. J Immunol 150, 3643-3650 (1993) (Pubitemid 23129745)
34. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P: Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy 51, 8-15 (1996) (Pubitemid 26104694)
35. Kahlert H, Grage-Griebenow E, Stuwe HT, Cromwell O, Fiebig H: T cell reactivity with allergoids: influence of the type of APC. J Immunol 165, 1807-1815 (2000) (Pubitemid 30643130)
36. Abraham R, Singh N, Mukhopadhyay A, Basu SK, Bal V, Rath S: Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages. J Immunol 154, 1-8 (1995)
37. Gordon S: Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 927-930 (2002) (Pubitemid 36044685)
38. Singh N, Bhatia S, Abraham R, Basu SK, George A, Bal V, et al: Modulation of T cell cytokine profiles and peptide-MHC complex availability in vivo by delivery to scavenger receptors via antigen maleylation. J Immunol 160, 4869-4880 (1998) (Pubitemid 28215321)
39. Spiegelberg HL, Horner AA, Takabayashi K, Raz E: Allergen- immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr Opin Allergy Clin Immunol 2, 547-551 (2002) (Pubitemid 36105820)
40. Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, et al: Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30, 1939-1947 (2000) (Pubitemid 30456190)
41. Bhatia S, Mukhopadhyay S, Jarman E, Hall G, George A, Basu SK, et al: Scavenger receptor-specific allergen delivery elicits IFN-gamma-dominated immunity and directs established TH2-dominated responses to a nonallergic phenotype. J Allergy Clin Immunol 109, 321-328 (2002) (Pubitemid 34158301)
42. Rajagopal D, Ganesh KA, Subba Rao PV: Modulation of allergen-specific immune responses to the major shrimp allergen, tropomyosin, by specific targeting to scavenger receptors on macrophages. Int Arch Allergy Immunol 121, 308-316 (2000) (Pubitemid 30229643)
43. Bohle B: AIC. Dynavax. Curr Opin Investig Drugs 4, 603-607 (2003)
44. Creticos PS, Lichtenstein LM: Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 94, 304-312 (2003)
45. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106, 124-134 (2000) (Pubitemid 30482862)
46. Lagares A, Puerta L, Caraballo L: [Polymorphism in allergens]. Biomedica 22, 51-62 (2002)
47. Griffith IJ, Pollock J, Klapper DG, Rogers BL, Nault AK: Sequence polymorphism of Amb a I and Amb a II, the major allergens in Ambrosia artemisiifolia (short ragweed). Int Arch Allergy Appl Immunol 96, 296-304 (1991)
48. Breiteneder H, Ferreira F, Hoffmann-Sommergruber K, Ebner C, Breitenbach M, Rumpold H, et al: Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Eur J Biochem 212, 355-362 (1993) (Pubitemid 23076101)
49. Swoboda I, Jilek A, Ferreira F, Engel E, Hoffmann-Sommergruber K, Scheiner O, et al: Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 270, 2607-2613 (1995)
50. Au LC, Lin ST, Peng HJ, Liang CC, Lee SS, Liao CD, et al: Molecular cloning and sequence analysis of fulllength cDNAs encoding new group of Cyn d 1 isoallergens. Allergy 57, 215-220 (2002) (Pubitemid 34250752)
51. Chang ZN, Peng HJ, Lee WC, Chen TS, Chua KY, Tsai LC, et al: Sequence polymorphism of the group 1 allergen of Bermuda grass pollen. Clin Exp Allergy 29, 488-496 (1999)
52. Muller WD, Karamfilov T, Kahlert H, Stuwe HT, Fahlbusch B, Cromwell O, et al: Mapping of T-cell epitopes of Phl p 5: evidence for crossreacting and noncrossreacting T-cell epitopes within Phl p 5 isoallergens. Clin Exp Allergy 28, 1538-1548 (1998) (Pubitemid 29003330)
53. Wurtzen P, Wissenbach M, Ipsen H, Bufe A, Arnved J, van Neerven RJ: Highly heterogeneous Phl p 5-specific T cells from patients with allergic rhinitis differentially recognize recombinant Phl p 5 isoallergens. J Allergy Clin Immunol 104, 115-122 (1999) (Pubitemid 29364489)
54. Helsper JP, Gilissen LJ, van Ree R, America AH, Cordewener JH, Bosch D: Quadrupole time-of-flight mass spectrometry: a method to study the actual expression of allergen isoforms identified by PCR cloning. J Allergy Clin Immunol 110, 131-138 (2002) (Pubitemid 36132739)
55. Hoffmann-Sommergruber K, Ferris R, Pec M, Radauer C, O'Riordain G, Laimer Da Camara Machado M, et al: Characterization of api g 1.0201, a new member of the Api g 1 family of celery allergens. Int Arch Allergy Immunol 122, 115-123 (2000) (Pubitemid 30435686)
56. Smith AM, Benjamin DC, Derewenda U, Smith WA, Thomas WR, Chapman MD: Sequence polymorphisms and antibody binding to the group 2 dust mite allergens. Int Arch Allergy Immunol 124, 61-63 (2001) (Pubitemid 32304762)
57. Smith WA, Hales BJ, Jarnicki AG, Thomas WR: Allergens of wild house dust mites: environmental der p 1 and der p 2 sequence polymorphisms. J Allergy Clin Immunol 107, 985-992 (2001) (Pubitemid 32523337)
58. Arquint O, Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ: Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 104, 1239-1243 (1999) (Pubitemid 30004986)
59. Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R, et al: Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 183, 599-609 (1996) (Pubitemid 26059521)
60. Wagner S, Radauer C, Bublin M, Hoffmann-Sommergruber K, Kopp T, Greisenegger EK, et al: Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J Allergy Clin Immunol 121, 246-252 (2008)
61. Lowenstein H, Sparholt SH, Klysner SS, Ipsen H, Larsen JN: The significance of isoallergenic variations in present and future specific immunotherapy. Int Arch Allergy Immunol 107, 285-289 (1995)
62. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101, 14677-14682 (2004) (Pubitemid 39346742)
63. Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, et al: Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives. Int Arch Allergy Immunol 118, 216-217 (1999) (Pubitemid 29195512)
64. van Hage-Hamsten M, Kronqvist M, Zetterstrom O, Johansson E, Niederberger V, Vrtala S, et al: Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104, 969-977 (1999) (Pubitemid 29532117)
65. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, et al: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. Faseb J 15, 2045-2047 (2001)
66. Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, et al: Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Int Arch Allergy Immunol 118, 218-219 (1999) (Pubitemid 29195513)
67. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 99, 1673-1681 (1997) (Pubitemid 27163818)
68. Wallner M, Stocklinger A, Thalhamer T, Bohle B, Vogel L, Briza P, et al: Allergy multivaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin Immunol 120, 374-380 (2007) (Pubitemid 47102390)
69. King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD: Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 166, 6057-5065 (2001)
70. Schramm G, Kahlert H, Suck R, Weber B, Stuwe HT, Muller WD, et al: "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgEbinding capacity but conserved T cell reactivity. J Immunol 162, 2406-2414 (1999) (Pubitemid 29288869)
71. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, et al: Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. Faseb J 16, 1301-1303 (2002)
72. Schmidt M, Hoffman DR: Expression systems for production of recombinant allergens. Int Arch Allergy Immunol 128, 264-270 (2002)
73. Aalberse RC, Akkerdaas J, van Ree R: Cross-reactivity of IgE antibodies to allergens. Allergy 56, 478-490 (2001) (Pubitemid 32521427)
74. Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ: Sensitization to cross-reactive carbohydrate determinants and the ubiquitous protein profilin: mimickers of allergy. Clin Exp Allergy 34, 137-144 (2004) (Pubitemid 38183692)
75. Mari A: IgE to cross-reactive carbohydrate determinants: analysis of the distribution and appraisal of the in vivo and in vitro reactivity. Int Arch Allergy Immunol 129, 286-295 (2002)
76. van der Veen MJ, van Ree R, Aalberse RC, Akkerdaas J, Koppelman SJ, Jansen HM, et al: Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. J Allergy Clin Immunol 100, 327-334 (1997) (Pubitemid 27402774)
77. van Ree R: Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases. Int Arch Allergy Immunol 129, 189-197 (2002) (Pubitemid 35365358)
78. Sorensen HP, Mortensen KK: Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115, 113-128 (2005) (Pubitemid 39656438)
79. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al: der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 104, 123-133 (1999) (Pubitemid 29534352)
80. Hewitt CR, Brown AP, Hart BJ, Pritchard DI: A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases. J Exp Med 182, 1537-1544 (1995)
81. Robinson C, Kalsheker NA, Srinivasan N, King CM, Garrod DR, Thompson PJ, et al: On the potential significance of the enzymatic activity of mite allergens to immunogenicity. Clues to structure and function revealed by molecular characterization. Clin Exp Allergy 27, 10-21 (1997) (Pubitemid 27051358)
82. Schulz O, Laing P, Sewell HF, Shakib F: der p I, a major allergen of the house dust mite, proteolytically cleaves the low-affinity receptor for human IgE (CD23). Eur J Immunol 25, 3191-3194 (1995)
83. Schulz O, Sewell HF, Shakib F: Proteolytic cleavage of CD25, the alpha subunit of the human T cell interleukin 2 receptor, by der p 1, a major mite allergen with cysteine protease activity. J Exp Med 187, 271-275 (1998) (Pubitemid 28060444)
84. Shakib F, Schulz O, Sewell H: A mite subversive: cleavage of CD23 and CD25 by der p 1 enhances allergenicity. Immunol Today 19, 313-316 (1998) (Pubitemid 28322327)
85. Hunt I: From gene to protein: a review of new and enabling technologies for multi-parallel protein expression. Protein Expr Purif 40, 1-22 (2005) (Pubitemid 40240966)
86. Cromwell O, Suck R, Kahlert H, Nandy A, Weber B, Fiebig H: Transition of recombinant allergens from bench to clinical application. Methods 32, 300-312 (2004) (Pubitemid 38201284)
87. Kleine-Tebbe J, Erdmann S, Knol EF, MacGlashan DW, Jr., Poulsen LK, Gibbs BF: Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int Arch Allergy Immunol 141, 79-90 (2006)
88. Budde IK, Aalbers M, Aalberse RC, van der Zee JS, Knol EF: Reactivity to IgE-dependent histamine-releasing factor is due to monomeric IgE. Allergy 55, 653-657 (2000) (Pubitemid 30438999)
89. Knol EF, Kuijpers TW, Mul FP, Roos D: Stimulation of human basophils results in homotypic aggregation. A response independent of degranulation. J Immunol 151, 4926-4933 (1993) (Pubitemid 23318546)
90. Siraganian RP: Refinements in the automated fluorometric histamine analysis system. J Immunol Methods 7, 283-290 (1975)
91. Vogel L, Luttkopf D, Hatahet L, Haustein D, Vieths S: Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system. Allergy 60, 1021-1028 (2005) (Pubitemid 40942756)
92. Mahler V, Vrtala S, Kuss O, Diepgen TL, Suck R, Cromwell O, et al: Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 34, 115-122 (2004) (Pubitemid 38183689)
93. Bartolomeo MP, Maisano F: Validation of a reversedphase HPLC method for quantitative amino acid analysis. J Biomol Tech 17, 131-137 (2006)
94. Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, et al: Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy. Int Arch Allergy Immunol 145, 193-206 (2008) (Pubitemid 351301311)
95. Kungl AJ, Susani M, Lindemann A, Machius M, Visser AJ, Scheiner O, et al: Evidence for an alpha helical T cell epitope in the C-terminus of the main birch pollen allergen Bet V 1. Biochem Biophys Res Commun 223, 187-192 (1996) (Pubitemid 26202498)
96. Dong A, Jones LS, Kerwin BA, Krishnan S, Carpenter JF: Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal Biochem 351, 282-289 (2006)
97. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 120, 25-85 (2007)
98. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116, 608-613 (2005) (Pubitemid 41267135)
99. Gafvelin G, Thunberg S, Kronqvist M, Gronlund H, Gronneberg R, Troye-Blomberg M, et al: Cytokine and antibody responses in birch-pollen- allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138, 59-66 (2005) (Pubitemid 41291566)